Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
about
Microbial synthesis of poly-γ-glutamic acid: current progress, challenges, and future perspectivesTargeted therapy using nanotechnology: focus on cancerCytokines as biomarkers of nanoparticle immunotoxicityPolymeric Nanostructures for Imaging and TherapyDevelopment of nanoscale approaches for ovarian cancer therapeutics and diagnosticsPharmacokinetics and tissue distribution of PGG-paclitaxel, a novel macromolecular formulation of paclitaxel, in nu/nu mice bearing NCI-460 lung cancer xenograftsPoly(ethylene oxide)-block-polyphosphester-based Paclitaxel Conjugates as a Platform for Ultra-high Paclitaxel-loaded Multifunctional Nanoparticles.Procoagulant inhibitory properties of paclitaxel poliglumex.Nanomedical engineering: shaping future nanomedicines.The Acinar Cage: Basement Membranes Determine Molecule Exchange and Mechanical Stability of Human Breast Cell AciniScience and technology of the emerging nanomedicines in cancer therapy: A primer for physicians and pharmacists.In vitro assessment of a novel polyrotaxane-based drug delivery system integrated with a cell-penetrating peptidePolymer conjugates as anticancer nanomedicines.Building Nanostructures with Drugs.Anticancer carrier-linked prodrugs in clinical trials.Polymer-drug conjugates as modulators of cellular apoptosis.Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates.Paclitaxel Nano-Delivery Systems: A Comprehensive Review.Treatment of performance status 2 patients with advanced non-small-cell lung cancer: what we know and what we don't know.Macromolecules as taxane delivery systems.Polymeric materials for theranostic applications.Objective: tumor. Strategies of drug targeting at the tumor mass level.Potential environmental implications of nano-enabled medical applications: critical review.Theranostic nanoparticles for cancer and cardiovascular applications.Role of polymer-drug conjugates in organ-specific delivery systems.Driving forces for drug loading in drug carriers.Anticancer Drug Delivery: An Update on Clinically Applied Nanotherapeutics.Synthetic Biomaterials from Metabolically Derived Synthons.Biodegradable polymers for targeted delivery of anti-cancer drugs.Low-molecular-weight polymer-drug conjugates for synergistic anticancer activity of camptothecin and doxorubicin combinationsEarly investigational tubulin inhibitors as novel cancer therapeutics.Dendritic polyglycerol sulfate as a novel platform for paclitaxel delivery: pitfalls of ester linkage.Polypeptide-Based Conjugates as Therapeutics: Opportunities and Challenges.Synthesis and characterization of cisplatin-loaded, EGFR-targeted biopolymer and in vitro evaluation for targeted delivery.Peptide-targeted polyglutamic acid doxorubicin conjugates for the treatment of alpha(v)beta(6)-positive cancers.Establishment of subcellular fractionation techniques to monitor the intracellular fate of polymer therapeutics I. Differential centrifugation fractionation B16F10 cells and use to study the intracellular fate of HPMA copolymer - doxorubicin.Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer."Grafting-from" synthesis and characterization of poly (2-ethyl-2-oxazoline)-b-poly (benzyl L-glutamate) micellar nanoparticles for potential biomedical applications.Preclinical development of drug delivery systems for paclitaxel-based cancer chemotherapy.Synthetic polypeptides: from polymer design to supramolecular assembly and biomedical application.
P2860
Q26745732-9219A48C-19B9-455B-AC81-B9866A57A1DAQ27023361-F5484502-1B2E-4702-B1BD-E1E335A4B426Q28383550-F5B6F9C6-F7F5-40EB-9706-9C3F0B329E1DQ30372383-E69F157E-5B22-4133-BC4B-CE9D04407B8DQ30421664-4686409F-F1B8-43EC-A876-9F419F565173Q33554366-9FBABBED-FC8F-454C-9A0E-5B639ABC6C91Q34069122-571DF975-52DE-4A41-94EA-733C0D280244Q34665903-32357747-BA2B-443B-979B-51E817755275Q35019550-C487A5E6-F7C3-4C2A-BF82-9FEE37D2302EQ35870478-60820639-1A93-4DA4-9928-0CD6FF9AA6F3Q36394925-9D22F48A-A966-4154-8CDE-B630D8CC07C1Q36397995-58C9E479-97AD-4E07-BEBD-F37AB5336C95Q36561667-2EC535A5-C62B-44AC-BBFA-AD60778523BBQ36766960-A0279F73-8DA9-4BB8-9411-EC68A4D9CB9EQ36861603-EAA80394-725D-47C5-905D-D033ADFEA1BAQ36956674-3011BEDD-DA76-4FE6-9CCB-9BAD981CB207Q37096500-E00DB91B-FEE2-4DC3-97F5-C5E0B92D9F3FQ37250009-DC60EFB8-DA92-48BA-8E27-8E1C9D9A0219Q37575622-604AEC05-E98D-4D60-8EE6-9BFFA7520F23Q37818236-FB5ACFA7-1870-4A60-83D7-0BBBD894545AQ38114360-FCF21D80-A6C4-41E7-804F-5C946E40C4AAQ38120976-9C451E5B-EA98-432B-92EE-024AEDADB3C9Q38193126-2246A1D1-50F2-4FB6-840F-0E1A387B15ABQ38193333-86C234BC-AE1D-4AA0-A983-E8C99CAEBF79Q38365556-9453C055-B582-4790-84AE-EEC743745A8EQ38366771-58982C63-4419-4CDA-82B2-075690BBEFD6Q38577297-716DFAF0-3B1D-4D3B-B361-2F3E5725DFBAQ38715187-4C171CDE-623C-4AF9-A3EB-193959970EFDQ38777436-0A5D5D5B-0D6B-4456-ACFB-4263DC58F9E6Q38778245-41BDE771-B5F7-4C74-8BE4-5DDA50108119Q38836161-C7869FD5-0E06-4533-82B3-9C08C0194E01Q38927851-9388940F-1A36-4E7A-A822-BB63A5E9A7BDQ38983708-2347DD9C-23FA-438B-BAE6-B92131A86239Q39334984-5968B448-7FF0-4140-BEDE-8F2B74E5F723Q39949731-077FC81D-EA38-48E9-B26F-E4FE09837F61Q40210618-1C4B7C69-F632-4174-800A-DDE4AE9EC607Q41897007-AAD5C763-8D9A-4EDF-A01A-098A012584FAQ45574185-D122A2B3-0852-4238-B88A-824426C320DFQ47621457-A8B2905C-C276-4398-A6D3-01B846C19D5CQ47638342-A8E84A94-FE96-4592-9BA4-D4FB5545E4D7
P2860
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
@ast
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
@en
type
label
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
@ast
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
@en
prefLabel
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
@ast
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane.
@en
P1476
Paclitaxel poliglumex (XYOTAX, CT-2103): a macromolecular taxane
@en
P2093
Jack W Singer
P304
P356
10.1016/J.JCONREL.2005.09.033
P407
P577
2005-11-16T00:00:00Z